SEATTLE and RICHMOND, BRITISH COLUMBIA - August 26, 2026 - Monod Bio, a Seattle-based AI-enabled protein design company, and SignalChem Biotech Inc., a wholly-owned subsidiary of Sino Biological, Inc. (SZSE: 301047), have announced a non-exclusive licensing agreement covering Monod Bio's proprietary LuxSit de novo luciferase technology and NovoBodies. This partnership allows SignalChem Biotech to incorporate these AI-designed proteins into its custom luminescent assay development and protein-fusion services for third-party customers in research settings.
The significance of this agreement lies in its potential to accelerate drug discovery processes. By integrating Monod Bio's advanced protein design tools, SignalChem Biotech can offer researchers more efficient pathways to identify high-quality discovery candidates. Dr. Rob Burgess, Chief Business Officer of Sino Biological, emphasized that this collaboration strengthens their ability to address complex biological questions and advance research programs more rapidly. The move also aligns with Sino Biological's broader strategy of incorporating AI-enabled technologies across its global life science tools and services portfolio.
Monod Bio's LuxSit is an AI-designed luciferase engineered for use in robust luminescent biosensors, while its NovoBodies are compact, highly stable binding proteins designed for high-performance recognition of various targets. Together, these technologies provide versatile tools for developing customized assays and discovery workflows. Daniel Silva Manzano, PhD, Chief Executive Officer of Monod Bio, noted that SignalChem Biotech and Sino Biological have the scientific expertise, customer reach, and service infrastructure to bring these technologies to a broad customer base. This partnership expands the reach of Monod Bio's platform and reinforces the value of its 'Monod Inside' model for integrating AI-designed proteins into commercial products and services.
The agreement is a strategic move for Sino Biological to enhance its specialized CRO capabilities, particularly in custom assay services. It underscores a growing trend in the life science industry towards leveraging AI-designed proteins to improve efficiency and accuracy in research. For Monod Bio, this licensing deal represents a validation of its technology and a pathway to broader commercial adoption. The non-exclusive nature of the agreement allows Monod Bio to pursue other partnerships, potentially increasing its market penetration.
While the financial impact of this agreement is not expected to be material for Sino Biological due to its broad product portfolio, it signals a commitment to innovation and AI integration. For researchers, the availability of these advanced tools through SignalChem Biotech's services could mean faster development of assays and better data quality, ultimately accelerating the pace of discovery in various therapeutic areas.
For more information about Sino Biological and SignalChem Biotech, visit www.sinobiological.com. For more about Monod Bio, visit monod.bio.
